*Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery DOI: http://dx.doi.org/10.5772/intechopen.83040*

intranasal delivery and evaluation on the targeting efficiency to the brain. International Journal of Pharmaceutics. 2004;**275**:85-96. DOI: 10.1016/j.ijph arm.2004.01.039

*Pharmaceutical Formulation Design - Recent Practices*

linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials.

[47] Mittal D et al. Insights into direct nose to brain delivery: Current status and future perspective. Drug Delivery.

[48] Md S et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. European Journal of Pharmaceutical

Sciences. 2013;**48**:393-405

2010;**18**:381-388

pol.2012.02.051

10.1208/pt070108

[49] Al-Ghananeem AM et al.

Intranasal drug delivery of didanosineloaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. Journal of Drug Targeting.

[50] Fazil M et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. European Journal of

Pharmaceutical Sciences. 2012;**47**:6-15

[51] Haque S et al. Venlafaxine loaded chitosan NPs for brain targeting:

[52] Vyas TK et al. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSci Tech Journal. 2006;**7**:E49-E57. DOI:

[53] Zhang Q et al. Preparation of nimodipine-loaded microemulsion for

Pharmacokinetic and pharmacodynamic evaluation. Carbohydrate Polymers. 2012;**89**:72-79. DOI: 10.1016/j.carb

[46] Chertok B et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials.

2011;**32**:4968-4975

2008;**29**:487-496

2014;**21**:75-86

nanoparticle-conjugated small-molecule activator of an epigenetic enzyme in the brain. Journal of Controlled Release.

[37] Kreuter J et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Research.

[38] Gulyaev AE et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research.

[39] Alyautdin RN et al. Delivery of loperamide across the bloodbrain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research.

[40] Musumeci T et al. PLA/PLGA nanoparticles for sustained release of docetaxel. International Journal of Pharmaceutics. 2006;**325**:172-179

[41] Li J, Sabliov C. PLA/PLGA

Reviews. 2013;**2**:241-257

nanoparticles for delivery of drugs across the blood-brain barrier. Nanotechnology

[42] Tsai Y-M et al. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. International Journal of Pharmaceutics. 2011;**416**:331-338

[43] Liu M et al. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Archives of Pharmacal Research. 2008;**31**:547-554

[44] Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. Journal of Nanoscience and Nanotechnology.

[45] Son S et al. A brain-targeted rabies virus glycoprotein-disulfide

2015;**217**:151-159

1995;**674**:171-174

1999;**16**:1564-1569

1997;**14**:325-328

**134**

2004;**4**:484-488

[54] Kumar M et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics. 2008;**358**:285-291. DOI: 10.1016/j.ijph arm.2008.03.029

[55] Alam MI et al. Intranasal administration of nanostructured lipid carriers containing CNS acting drug: Pharmacodynamic studies and estimation in blood and brain. Journal of Psychiatric Research. 2012;**46**:1133-1138. DOI: 10.1016/j.jpsychires.2012.05.014

[56] Jain R et al. Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine. 2010;**5**:575-587. DOI: 10.2217/nnm.10.28

[57] Jain R et al. Micellar Nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharmaceutical Research. 2010;**27**:655- 664. DOI: 10.1007/s11095-009-0041-x

[58] Kanazawa T. Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Medical Devices (Auckland, NZ). 2015;**8**:57-64. DOI: 10.2147/mder.s70856

[59] Allard E et al. Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. Pharmaceutical Research. 2010;**27**:56

[60] Lollo G et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. International Journal of Pharmaceutics. 2015;**495**:972-980

[61] Corem-Salkmon E et al. Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. International Journal of Nanomedicine. 2011;**6**:1595

[62] Huynh NT et al. Administrationdependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. International Journal of Pharmaceutics. 2012;**423**:55-62

[63] Laine A-L et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics. 2012;**81**:690-693

[64] Huynh NT et al. Treatment of 9L gliosarcoma in rats by ferrociphenolloaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharmaceutical Research. 2011;**28**:3189-3198

[65] Qian X et al. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials. 2014;**35**:2322-2335

[66] Guerin C et al. Recent advances in brain tumor therapy: Local intracerebral drug delivery by polymers. Investigational New Drugs. 2004;**22**:27-37

[67] Hwang SR, Kim K. Nano-enabled delivery systems across the bloodbrain barrier. Archives of Pharmacal Research. 2014;**37**:24-30

[68] Bleyer WA et al. The Ommaya reservoir. Newly recognized complications and recommendations for insertion and use. Cancer. 1978;**41**:2431-2437

[69] Härtig W et al. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: Implications for

targeting β-amyloid in Alzheimer's disease. Neuroscience Letters. 2003;**338**:174-176

[70] Alyautdin R et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. Journal of Microencapsulation. 1998;**15**:67-74

[71] Joshi S, Emala CW, Pile-Spellman J. Intra-arterial drug delivery: A concise review. Journal of Neurosurgical Anesthesiology. 2007;**19**:111-119

[72] Yang HW et al. Non-invasive synergistic treatment of brain tumors by targeted chemotherapeutic delivery and amplified focused ultrasoundhyperthermia using magnetic nanographene oxide. Advanced Materials. 2013;**25**:3605-3611

[73] Mulik RS et al. Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. Biomaterials. 2016;**83**:257-268

[74] Yao L et al. Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubbleenhanced unfocused ultrasound. Biomaterials. 2014;**35**:3384-3395

[75] Yin T et al. Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials. 2013;**34**:4532-4543

[76] Thakur S, Sharma P, Malviya R. Review: Recent strategies involved in brain targeting through ocular routepatents and application. Annals of Pharmacology and Pharmaceutics. 2017;**2**(8):1043

[77] Capsoni S et al. Delivery of NGF to the brain: Intranasal versus ocular

administration in anti-NGF transgenic mice. Journal of Alzheimer's Disease. 2009;**16**:371-388

[78] Abdulrazik M. Method for central nervous system targeting through the ocular route of drug delivery. Google Patents. 2003

[79] Gao X et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. Journal of Controlled Release. 2007;**121**:156-167. DOI: 10.1016/j.jconrel.2007.05.026

[80] Raliya R et al. Non-invasive aerosol delivery and transport of gold nanoparticles to the brain. Scientific Reports. 2017;**7**:44718. DOI: 10.1038/srep44718 Available from: https://www.nature.com/ articles/srep44718#supplementaryinformation

[81] Mishra V et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. Journal of Drug Targeting. 2006;**14**:45-53

[82] Darius J et al. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. Journal of Pharmacy and Pharmacology. 2000;**52**:1043-1047

[83] Wilson B et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (n-butylcyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. 2008;**70**:75-84

[84] Bteich J et al. A novel nanoparticle formulation derived from carboxymethyl-cellulose, polyethylene glycol and cabazitaxel for chemotherapy delivery to the

**137**

*Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery*

[93] Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biological and Pharmaceutical

[94] Ranganath SH et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010;**31**:5199-5207

[95] Kim D-H, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials. 2006;**27**:3031-3037

[96] Karthivashan G et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease. Drug Delivery.

2018;**25**:307-320

Bulletin. 2006;**29**:397-402

*DOI: http://dx.doi.org/10.5772/intechopen.83040*

brain. Bioconjugate Chemistry.

[85] Yang Z-Z et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials.

[86] Haney MJ et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of Controlled Release.

hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified

Alzheimer's disease mice using magnetic resonance imaging (MRI). Biomaterials.

silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Journal of Controlled Release. 2015;**207**:31-39

nanogels. Journal of Drug Targeting.

[88] Cheng KK et al. Curcuminconjugated magnetic nanoparticles for detecting amyloid plaques in

[89] Costa PM et al. MiRNA-21

[90] Aktaş Y et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chemistry.

[91] Chen P-Y et al. Novel magnetic/ ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro-Oncology.

nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Research.

2018;**29**(6):2009-2020

2014;**35**:5226-5239

2015;**207**:18-30

2006;**14**:87-95

2015;**44**:155-172

2005;**16**:1503-1511

2010;**12**:1050-1060

2006;**66**:2801-2806

[92] Noble CO et al. Novel

[87] Soni S et al. Delivery of

*Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery DOI: http://dx.doi.org/10.5772/intechopen.83040*

brain. Bioconjugate Chemistry. 2018;**29**(6):2009-2020

*Pharmaceutical Formulation Design - Recent Practices*

administration in anti-NGF transgenic mice. Journal of Alzheimer's Disease.

[78] Abdulrazik M. Method for central nervous system targeting through the ocular route of drug delivery. Google

[79] Gao X et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. Journal of Controlled Release. 2007;**121**:156-167. DOI: 10.1016/j.jconrel.2007.05.026

[80] Raliya R et al. Non-invasive aerosol delivery and transport of gold nanoparticles to the brain. Scientific Reports. 2017;**7**:44718. DOI: 10.1038/srep44718 Available from: https://www.nature.com/ articles/srep44718#supplementary-

[81] Mishra V et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. Journal of Drug Targeting. 2006;**14**:45-53

[82] Darius J et al. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. Journal of Pharmacy and Pharmacology.

[83] Wilson B et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (n-butylcyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics.

2000;**52**:1043-1047

2008;**70**:75-84

[84] Bteich J et al. A novel

nanoparticle formulation derived from carboxymethyl-cellulose, polyethylene glycol and cabazitaxel for chemotherapy delivery to the

2009;**16**:371-388

Patents. 2003

information

targeting β-amyloid in Alzheimer's disease. Neuroscience Letters.

[70] Alyautdin R et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. Journal of Microencapsulation. 1998;**15**:67-74

[71] Joshi S, Emala CW, Pile-Spellman J. Intra-arterial drug delivery: A concise review. Journal of Neurosurgical Anesthesiology. 2007;**19**:111-119

[72] Yang HW et al. Non-invasive synergistic treatment of brain tumors by targeted chemotherapeutic delivery and amplified focused ultrasoundhyperthermia using magnetic nanographene oxide. Advanced Materials. 2013;**25**:3605-3611

[73] Mulik RS et al. Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound.

Biomaterials. 2016;**83**:257-268

[74] Yao L et al. Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubbleenhanced unfocused ultrasound. Biomaterials. 2014;**35**:3384-3395

[75] Yin T et al. Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials.

[76] Thakur S, Sharma P, Malviya R. Review: Recent strategies involved in brain targeting through ocular routepatents and application. Annals of Pharmacology and Pharmaceutics.

[77] Capsoni S et al. Delivery of NGF to the brain: Intranasal versus ocular

2013;**34**:4532-4543

2017;**2**(8):1043

2003;**338**:174-176

**136**

[85] Yang Z-Z et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;**35**:5226-5239

[86] Haney MJ et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of Controlled Release. 2015;**207**:18-30

[87] Soni S et al. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. Journal of Drug Targeting. 2006;**14**:87-95

[88] Cheng KK et al. Curcuminconjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer's disease mice using magnetic resonance imaging (MRI). Biomaterials. 2015;**44**:155-172

[89] Costa PM et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Journal of Controlled Release. 2015;**207**:31-39

[90] Aktaş Y et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chemistry. 2005;**16**:1503-1511

[91] Chen P-Y et al. Novel magnetic/ ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro-Oncology. 2010;**12**:1050-1060

[92] Noble CO et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Research. 2006;**66**:2801-2806

[93] Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biological and Pharmaceutical Bulletin. 2006;**29**:397-402

[94] Ranganath SH et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010;**31**:5199-5207

[95] Kim D-H, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials. 2006;**27**:3031-3037

[96] Karthivashan G et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease. Drug Delivery. 2018;**25**:307-320

**139**

**Chapter 8**

**Abstract**

**1. Introduction to 3D printing**

3D Printing in Pharmaceutical

The pharmaceutical industry is moving ahead at a rapid pace. Modern technology has enabled the development of novel dosage forms for targeted therapy. However, the fabrication of novel dosage forms at industrial scale is limited and the industry still runs on conventional drug delivery systems, especially modified tablets. The introduction of 3D printing technology in the pharmaceutical industry has opened new horizons in the research and development of printed materials and devices. The main benefits of 3D printing technology lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes, and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalized medicines becoming a reality. This chapter provides an overview of how 3D printed technology has extended from initial unit operations to developed final products.

**Keywords:** 3D print, personalized medicines, manufacturing, drug delivery

Gaining immense interest both in academic and industrial sector is the concept of three dimensional (3D) printing (3DP) technologies. Domains like aerospace, engineering, FMCG, architecture, military, fashion industry, chemical industry, and medical field are by no way untouched by this technology [1, 2]. 3DP has a wide range of applications like tissue design, printing of organ, diagnostics, manufacture of biomedical devices, and the design of drug and delivery systems in the medical field [3, 4]. From the data originated by various techniques like computed tomography (CT) scan and magnetic resonance imaging (MRI), complex anatomical and medical structures according to the need of patient can be fabricated [5, 6]. Replacing and repairing the defective organs like kidney, heart etc. or all together creating a new organ that mimics the same functions as that of original are some additional uses of this technology [7]. This technology is so widespread that its applications include things that are an integral part of human life like clothing, eyeglasses, jewelry, parts of cars, and drugs that can be printed in almost any geometry and shape as per the requirement of the user [8].

In this technology a concept is transformed into prototype by taking help from 3D computer-aided design (CAD) files, hence digitally controlled and customized product can be fabricated [9]. This technology utilizes a bottom-up approach in which layers of materials like living cells, wood, alloy, thermoplastic, metals etc. are placed on top of each other in order to make the required 3D object [10]. Therefore, 3D printing is also known by other terminologies such as layered manufacturing, additive manufacturing, computer automated manufacturing, rapid

prototyping, or solid freeform technology (SFF) [9].

Sector: An Overview

*Asad Ali, Usama Ahmad and Juber Akhtar*
